Qiming’s holding company Broncus is on HKEx board of directors


SHANGHAI, seven. 24, 2021 / PRNewswire / – Broncus, a holding company of Qiming Venture Partners (SEHK: 2216), a pioneer in the from China market for interventional pulmonary navigation devices, now listed on the main board of the Hong Kong Stock Exchange. The issue price is HK $ 18.7/ share, representing a market capitalization of almost 10 billion Hong Kong dollars.

Qiming Venture Partners invested in Broncus in Series A in 2014 and continued in Rounds B and C. As the first investor, Qiming was the largest institutional shareholder of the company prior to its IPO. The Broncus listing is the ninth public listing in Qiming’s portfolio in 2021.

Broncus’ strategic investors include international industry giant Intuitive Surgical (NASDAQ: ISRG), a global technology leader in robot-assisted and minimally invasive surgical platforms and diagnostic tools, and the manufacturer of surgical robots world famous da Vinci. Key investors in Broncus’ IPO include Springhill Fund, Qiming’s public equity unit.

Founded in 2012, Broncus is committed to providing innovative diagnostic and therapeutic solutions in interventional pulmonology in China and globally. Excelling in real-time image-based pulmonary navigation technologies, the company’s platform has solved the challenges of current diagnostic and treatment paradigms and addressed the unmet medical needs of lung disease.

Broncus flagship products include the InterVapor system and RF-II. The InterVapor system is the world’s first and only thermal vapor energy ablation system to treat lung diseases, including COPD (chronic obstructive pulmonary disease) and lung cancer, according to Frost & Sullivan. The self-developed RF-II is the only radiofrequency catheter ablation system that specifically targets lung cancer. To date, Broncus held 132 and 60 patents and patent applications related to InterVapor and RF-II, respectively.

Broncus has gained a significant competitive advantage through an efficient R&D model, global marketing capabilities and strong production capacity. The company offers three commercialized navigation devices, while most international competitors only offer one product. Broncus ranked first in from China Interventional respiratory navigation devices market with a market share of 43.2% measured by sales volume for the years 2018, 2019 and 2020, according to Frost & Sullivan.

Guowei Zhan, CEO of Broncus, said: “The IPO is an important milestone for Broncus. We will continue to promote product R&D, achieve rapid iteration of products, and strengthen our cooperation with global KOLs, from innovative concepts, from product development to technology promotion. market demand and facilitate the global commercialization of our products, as well as increasing investments in AI and machine learning to optimize solutions for patients with lung disease. distributor of innovative medical technologies and solutions. “

Nisa Leung, Managing Partner of Qiming Venture Partners, said, “Qiming has worked alongside the Broncus team since our initial investment in 2014. The team has a global vision, high capabilities and a proven track record. With Broncus passing the IPO milestone, we hope the company will continue to promote interventional diagnostics and therapeutic solutions as the gold standard for the treatment of lung disease and become a leading global company. Qiming will continue to give full support to innovative enterprises in the long term and facilitate the development of the industry.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leader China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages nine US dollars funds and six RMB funds with $ 5.9 billion in assets under management. Since our inception, we have invested in outstanding companies in the TMT and healthcare industries in the start-up and growth stages.

Since our inception, we have supported more than 380 innovative and fast growing companies. Over 130 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or have successfully exited through mergers and acquisitions and other means . There are also over 40 portfolio companies that have achieved unicorn status.

Many of the companies in our portfolio today are the most influential companies in their respective industries, including Xiaomi (SEHK: 1810), Meituan (SEHK: 3690), Bilibili (NASDAQ: BILI, SEHK: 9626), Roborock (SHSE : 688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE: 300347, SEHK: 3347), Zaï laboratory (NASDAQ: ZLAB, SEHK: 9688), Venus MedTech (SEHK: 2500), CanSino Biologics (SEHK: 6185, SHSE: 688185), Schrödinger (NASDAQ: SDGR), APT Medical (SHSE: 688617), Sanyou Medical (SHSE: 688085), New Horizon Health (SEHK: 6606), AmoyDx (SZSE: 300685), Berry Genomics (SZSE: 000710), SinocellTech (SHSE: 688520), WeDoctor Group and UBTech among many others.

SOURCE Qiming Venture Partners


About Dwaine Pinson

Check Also

Venture Capital signs a €35 million investment agreement with 2 fund managers to support SMEs

The Venture Capital Trust Fund (VCTF) has reached an agreement with two fund managers, Mirepa …

Leave a Reply

Your email address will not be published.